Form 4: Nuvalent CFO Sells Shares Under 10b5-1 Plan

Nuvalent's Chief Financial Officer, Alexandra Balcom, has executed a Rule 10b5-1 trading plan, resulting in the sale of company stock and the acquisition of stock options.

Summary

• Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc., reported transactions on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.
• The plan involved the sale of 3,544 shares at a weighted average price of $104.39, 5,417 shares at $105.30, and 2,469 shares at $106.18.
• Additionally, 11,430 shares were acquired at a price of $1.08, and a stock option for 11,430 shares with an exercise price of $1.08 was granted.
• These transactions are part of a structured plan designed to comply with Rule 10b5-1(c) affirmative defense conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading, making it a routine disclosure.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock sales, which can be viewed positively for corporate governance and transparency.
• The acquisition of stock options at a low exercise price ($1.08) suggests potential future upside for the reporting person, contingent on stock performance.

Negatives

• The sale of a significant number of shares by the CFO could be interpreted as a lack of confidence in the short-term stock performance, although it is executed under a pre-planned strategy.
• The weighted average sale prices range from $103.81 to $106.69, indicating a substantial value of shares disposed of by a key executive.

Risks

• The primary risk associated with such filings is the market's interpretation of insider selling, which can negatively impact investor sentiment and stock price, despite the Rule 10b5-1 plan.
• Future stock price performance is inherently uncertain, and the value of the acquired stock options is directly tied to this performance.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. However, the acquisition of stock options by the CFO suggests an expectation of future stock value appreciation.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.
• The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage personal portfolios while adhering to regulatory requirements. The execution of such plans by a CFO in a company like Nuvalent, which operates in the oncology drug development space, is a standard practice for managing potential conflicts of interest and avoiding insider trading accusations.

Stakeholder Impact

• Shareholders: May interpret the CFO's stock sales as a negative signal, potentially impacting short-term stock price, despite the Rule 10b5-1 plan.
• Employees: Similar to shareholders, employees holding company stock may react to insider selling.
• Management: The CFO's actions are within established legal frameworks for managing personal investments.

Next Steps

• The reporting person may continue to execute transactions under the existing Rule 10b5-1 plan.
• The company may provide further updates on executive stock transactions in subsequent filings.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Share Sales, Chief Financial Officer, Alexandra Balcom, Beneficial Ownership